P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA

• N. G. Daver,
• P. Vyas,
• M. P. Chao,
• G. Xing,
• C. Renard,
• G. Ramsingh,
• D. A. Sallman,
• A. H. Wei

Affiliations

N. G. Daver

1 The University of Texas MD Anderson Cancer Center, Houston, United States of America

P. Vyas

2 Weatherall Institute of Molecular Medicine, MRC Molecular Hematology Unit, University of Oxford, Oxford, United Kingdom

M. P. Chao

3 Gilead Sciences, Inc., Foster City

G. Xing

3 Gilead Sciences, Inc., Foster City

C. Renard

3 Gilead Sciences, Inc., Foster City

G. Ramsingh

3 Gilead Sciences, Inc., Foster City

D. A. Sallman

4 Moffitt Cancer Center, Tampa, United States of America

A. H. Wei

5 Department of Haematology, Alfred Hospital and Monash University, Melbourne, Australia